Skip to Content for Robert Lazarus Menu for Robert Lazarus About Us Menu Research Menu Development Menu Medicines Menu Investors Menu Media Menu Careers Menu
Banner Image

Robert Lazarus

Robert Lazarus
Robert Lazarus Principal Scientist: Protein Engineering

Mentor Profile | Top Scientific Papers

Top Scientific Papers

  • Kirchhofer D, Lipari MT, Santell L, Billeci KL, Maun HR, Sandoval WN, Moran P, Ridgway J, Eigenbrot C, Lazarus RA. Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist. Proc Natl Acad Sci U S A 2007 Mar 27; 104(13): 5306-11. Epub 2007 Mar 19. View Abstract on PubMed

  • Lazarus RA, Olivero AG, Eigenbrot C, Kirchhofer D. Inhibitors of Tissue Factor.Factor VIIa for anticoagulant therapy. Curr Med Chem 2004 Sep; 11(17): 2275-90. View Abstract on PubMed

  • Kirchhofer D, Yao X, Peek M, Eigenbrot C, Lipari MT, Billeci KL, Maun HR, Moran P, Santell L, Wiesmann C, Lazarus RA. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling. J Biol Chem 2004 Sep 17; 279(38): 39915-24. View Abstract on PubMed

  • Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J 2004 Jun 16; 23(12): 2325-35. View Abstract on PubMed

  • Maun HR, Eigenbrot C, Lazarus RA. Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage. J Biol Chem 2003 Jun 13; 278(24): 21823-30. View Abstract on PubMed

  • Roberge M, Santell L, Dennis MS, Eigenbrot C, Dwyer MA, Lazarus RA. A novel exosite on coagulation factor VIIa and its molecular interactions with a new class of peptide inhibitors. Biochemistry 2001 Aug 14; 40(32): 9522-31. View Abstract on PubMed

  • Dennis MS, Roberge M, Quan C, Lazarus RA. Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa. Biochemistry 2001 Aug 14; 40(32): 9513-21. View Abstract on PubMed

  • Dennis MS, Eigenbrot C, Skelton NJ, Ultsch MH, Santell L, Dwyer MA, O'Connell MP, Lazarus RA. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature 2000 Mar 30; 404(6777): 465-70. View Abstract on PubMed

  • Pan CQ, Dodge TH, Baker DL, Prince WS, Sinicropi DV, Lazarus RA. Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus. J Biol Chem 1998 Jul 17; 273(29): 18374-81. View Abstract on PubMed

  • Pan CQ, Lazarus RA. Hyperactivity of human DNase I variants. Dependence on the number of positively charged residues and concentration, length, and environment of DNA. J Biol Chem 1998 May 8; 273(19): 11701-8. View Abstract on PubMed

  • Pan CQ, Ulmer JS, Herzka A, Lazarus RA. Mutational analysis of human DNase I at the DNA binding interface: implications for DNA recognition, catalysis, and metal ion dependence. Protein Sci 1998 Mar; 7(3): 628-36. View Abstract on PubMed

  • Pan CQ, Lazarus RA. Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism. Biochemistry 1997 Jun 3; 36(22): 6624-32. View Abstract on PubMed

  • Ulmer JS, Herzka A, Toy KJ, Baker DL, Dodge AH, Sinicropi D, Shak S, Lazarus RA. Engineering actin-resistant human DNase I for treatment of cystic fibrosis. Proc Natl Acad Sci U S A 1996 Aug 6; 93(16): 8225-9. View Abstract on PubMed

  • Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. J Biol Chem 1994 Sep 2; 269(35): 22137-44. View Abstract on PubMed

  • Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display. J Biol Chem 1994 Sep 2; 269(35): 22129-36. View Abstract on PubMed

  • Krezel AM, Wagner G, Seymour-Ulmer J, Lazarus RA. Structure of the RGD protein decorsin: conserved motif and distinct function in leech proteins that affect blood clotting. Science 1994 Jun 24; 264(5167): 1944-7. View Abstract on PubMed

  • Seymour JL, Lindquist RN, Dennis MS, Moffat B, Yansura D, Reilly D, Wessinger ME, Lazarus RA. Ecotin is a potent anticoagulant and reversible tight-binding inhibitor of factor Xa. Biochemistry 1994 Apr 5; 33(13): 3949-58. View Abstract on PubMed

  • Adler M, Lazarus RA, Dennis MS, Wagner G. Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science 1991 Jul 26; 253(5018): 445-8. View Abstract on PubMed

  • Seymour JL, Henzel WJ, Nevins B, Stults JT, Lazarus RA. Decorsin. A potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor from the leech Macrobdella decora. J Biol Chem 1990 Jun 15; 265(17): 10143-7.

  • Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, Bunting S, Lazarus RA. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci USA 1990 Apr; 87(7): 2471-5. View Abstract on PubMed

  • Anderson S, Marks CB, Lazarus R, Miller J, Stafford K, Seymour J, Light D, Rastetter W, Estell D. Production of 2-Keto-L-Gulonate, an Intermediate in L-Ascorbate Synthesis, by a Genetically Modified Erwinia herbicola. Science 1985 Oct 11; 230(4722): 144-149.

Books

  • Lazarus RA, Wagener JS. Recombinant Human Deoxyribonuclease I. In Pharmaceutical Biotechnology, 3rd ed., Crommelin DJA, Sindelar RD, Meibohm B, eds., Informa Healthcare USA Inc., New York, Ch. 19, 387-398 (2007).

  • Lazarus RA. Deoxyribonucleases. In Wiley Encyclopedia of Molecular Medicine. John Wiley & Sons, Inc., New York, 1025-1028 (2002).

  • Lazarus RA, Seymour JL, Stafford RK, Marks CB Anderson S. Vitamin C: Bioconversion via a Recombinant DNA Approach. In Genetics and Molecular Biology of Industrial Microorganisms, C.L. Hershberger, S.W. Queener, and G. Hegeman, eds., American Society for Microbiology, Washington, D.C., 187-193 (1989).